Related Experiment Videos
[A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese
1Department of Endocrinology, Rui-jin Hospital, Shanghai 2nd Medical University, Shanghai 200025, China.
Objectives:
To assess weight loss efficacy, safety and tolerability of sibutramine in simple obese subjects.
Methods:
Randomized, double-blind, placebo-controlled clinical trial. Four hospital outpatient clinics in Shanghai, Chongqing, Shandong and Tianjin, respectively.
Participants:
233 men and women, 18-65 years old, with body mass index (BMI) ranging from 27 to 40 kg/m2 were randomly divided into an intervened group and a placebo control group. Sibutramine 10 mg or placebo once a day.
Main Outcome Measures:
Body weight, routine laboratory and clinical safety monitoring.
Results:
Of 233 eligible patients, 120 received sibutramine and 113 placebo. Weight reduction was significantly greater in the intervented group (6.8 +/- 3.1) kg than the placebo control group (0.48 +/- 2.6) kg from week 4 onwards to week 24 (P < 0.001). Some minor side effects were noticed in the subjects who took sibutramine. But the symptoms were light and short term. Sibutramine was well tolerated.
Conclusions:
Sibutramine 10 mg once a day is an effective and safe therapy for weight reduction in simple over-weighted and obese subjects.